Indication
Solid Tumors Harboring NRG1 Fusion
1 clinical trial
1 product
Clinical trial
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)Status: Recruiting, Estimated PCD: 2026-12-31
Product
Zenocutuzumab